Consolidated Q2 FY27 revenue Rs 873.9 cr, PAT Rs 193.9 cr, both up year on year; dividend Rs 5
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations was Rs 873.9 crore against Rs 730.6 crore in the year-ago quarter, up 19.6%, and profit after tax was Rs 193.9 crore against Rs 152.2 crore, up 27.4%. EBITDA margin widened to about 32.0% from 30.7%. The board declared a second interim dividend of Rs 5 per share and approved up to Rs 49.5 crore of further funding for the Dubai subsidiary.
Profit growth, wider margins and Rs 5 dividend should support the stock; operating cash flow is strong, though overseas expansion uses cash.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.